A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

NCT03493542 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

766

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

Interventions

BIOLOGICAL: V501

Sponsor

Merck Sharp & Dohme LLC